Cargando…
Risk Factors Affecting Adverse Effects of Cyclosporine A in a Real-World Psoriasis Treatment
BACKGROUND: No study to date has focused on the changes in laboratory test results and related risk factors in patients with psoriasis treated with prolonged Cyclosporine A (CsA) therapy. OBJECTIVE: The objective of this study was to investigate the changes of laboratory values and related risk fact...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
The Korean Dermatological Association; The Korean Society for Investigative Dermatology
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5839884/ https://www.ncbi.nlm.nih.gov/pubmed/29606810 http://dx.doi.org/10.5021/ad.2018.30.2.143 |
_version_ | 1783304484271685632 |
---|---|
author | Kim, Bo Ri Yang, Seungkeol Doh, Eun Jin Choi, Chong Won Youn, Sang Woong |
author_facet | Kim, Bo Ri Yang, Seungkeol Doh, Eun Jin Choi, Chong Won Youn, Sang Woong |
author_sort | Kim, Bo Ri |
collection | PubMed |
description | BACKGROUND: No study to date has focused on the changes in laboratory test results and related risk factors in patients with psoriasis treated with prolonged Cyclosporine A (CsA) therapy. OBJECTIVE: The objective of this study was to investigate the changes of laboratory values and related risk factors in patients with psoriasis treated with CsA in a real-world setting. METHODS: Records of patients with psoriasis treated with CsA at an outpatient clinic were collected, and a Cox proportional hazards regression model was used. RESULTS: Of the 128 patients included in this study, 28 patients (21.9%) showed laboratory test abnormalities over a mean medication period of 11.6 months. Older age (hazard ratio [HR], 1.174; 95% confidence interval [CI], 1.068~1.370; p=0.007) and pre-existing kidney disease (HR, 0.008; 95% CI, 0~0.205; p=0.001) significantly increased the risk of renal dysfunction. Male sex was the only significant risk factor for liver enzyme elevation (HR, 0.284; 95% CI, 0.081~0.784; p=0.026) and uric acid abnormality (HR, 0.048; 95% CI, 0~0.372; p=0.046). CONCLUSION: This is an in-depth analysis of laboratory changes and related risk factors in patients with psoriasis treated with CsA. Liver is the most commonly affected organ of CsA toxicity. Older age, male sex, and presence of kidney disease were risk factors associated with laboratory abnormality during CsA treatment. |
format | Online Article Text |
id | pubmed-5839884 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2018 |
publisher | The Korean Dermatological Association; The Korean Society for Investigative Dermatology |
record_format | MEDLINE/PubMed |
spelling | pubmed-58398842018-04-01 Risk Factors Affecting Adverse Effects of Cyclosporine A in a Real-World Psoriasis Treatment Kim, Bo Ri Yang, Seungkeol Doh, Eun Jin Choi, Chong Won Youn, Sang Woong Ann Dermatol Original Article BACKGROUND: No study to date has focused on the changes in laboratory test results and related risk factors in patients with psoriasis treated with prolonged Cyclosporine A (CsA) therapy. OBJECTIVE: The objective of this study was to investigate the changes of laboratory values and related risk factors in patients with psoriasis treated with CsA in a real-world setting. METHODS: Records of patients with psoriasis treated with CsA at an outpatient clinic were collected, and a Cox proportional hazards regression model was used. RESULTS: Of the 128 patients included in this study, 28 patients (21.9%) showed laboratory test abnormalities over a mean medication period of 11.6 months. Older age (hazard ratio [HR], 1.174; 95% confidence interval [CI], 1.068~1.370; p=0.007) and pre-existing kidney disease (HR, 0.008; 95% CI, 0~0.205; p=0.001) significantly increased the risk of renal dysfunction. Male sex was the only significant risk factor for liver enzyme elevation (HR, 0.284; 95% CI, 0.081~0.784; p=0.026) and uric acid abnormality (HR, 0.048; 95% CI, 0~0.372; p=0.046). CONCLUSION: This is an in-depth analysis of laboratory changes and related risk factors in patients with psoriasis treated with CsA. Liver is the most commonly affected organ of CsA toxicity. Older age, male sex, and presence of kidney disease were risk factors associated with laboratory abnormality during CsA treatment. The Korean Dermatological Association; The Korean Society for Investigative Dermatology 2018-04 2018-02-21 /pmc/articles/PMC5839884/ /pubmed/29606810 http://dx.doi.org/10.5021/ad.2018.30.2.143 Text en Copyright © 2018 The Korean Dermatological Association and The Korean Society for Investigative Dermatology http://creativecommons.org/licenses/by-nc/4.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Original Article Kim, Bo Ri Yang, Seungkeol Doh, Eun Jin Choi, Chong Won Youn, Sang Woong Risk Factors Affecting Adverse Effects of Cyclosporine A in a Real-World Psoriasis Treatment |
title | Risk Factors Affecting Adverse Effects of Cyclosporine A in a Real-World Psoriasis Treatment |
title_full | Risk Factors Affecting Adverse Effects of Cyclosporine A in a Real-World Psoriasis Treatment |
title_fullStr | Risk Factors Affecting Adverse Effects of Cyclosporine A in a Real-World Psoriasis Treatment |
title_full_unstemmed | Risk Factors Affecting Adverse Effects of Cyclosporine A in a Real-World Psoriasis Treatment |
title_short | Risk Factors Affecting Adverse Effects of Cyclosporine A in a Real-World Psoriasis Treatment |
title_sort | risk factors affecting adverse effects of cyclosporine a in a real-world psoriasis treatment |
topic | Original Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5839884/ https://www.ncbi.nlm.nih.gov/pubmed/29606810 http://dx.doi.org/10.5021/ad.2018.30.2.143 |
work_keys_str_mv | AT kimbori riskfactorsaffectingadverseeffectsofcyclosporineainarealworldpsoriasistreatment AT yangseungkeol riskfactorsaffectingadverseeffectsofcyclosporineainarealworldpsoriasistreatment AT doheunjin riskfactorsaffectingadverseeffectsofcyclosporineainarealworldpsoriasistreatment AT choichongwon riskfactorsaffectingadverseeffectsofcyclosporineainarealworldpsoriasistreatment AT younsangwoong riskfactorsaffectingadverseeffectsofcyclosporineainarealworldpsoriasistreatment |